QPPV.COM

How the EU Medicines Regulatory System Works

A structured foundation for understanding how EU medicines regulation works, from Union legislation and marketing authorisation through scientific assessment, national implementation and post-authorisation oversight.

Audio Lesson 22 min
Knowledge Assessment Test your understanding of this article. Take the assessment →

How the EU Medicines Regulatory System Works

Overall structure

This article is the foundation of the EU Regulatory Affairs series. It explains the architecture of the European medicines regulatory system before moving into individual procedures, committees and legal provisions.

The article follows the regulatory lifecycle rather than treating EU medicines regulation as a collection of isolated agencies and acronyms.

  1. Purpose and architecture of the EU medicines regulatory system
  2. The legal foundation of EU medicines regulation
  3. The European regulatory network
  4. Marketing authorisation as the central regulatory concept
  5. Centralised and national authorisation routes
  6. MRP and DCP
  7. EMA, European Commission and national competent authorities
  8. CHMP, PRAC and CMDh
  9. Scientific assessment versus legal decision-making
  10. The regulatory lifecycle after authorisation
  11. Pharmacovigilance and risk management
  12. Variations, referrals and other post-authorisation procedures
  13. Implementation across Member States
  14. Regulatory information and document hierarchy
  15. How the system should be interpreted by an MAH and QPPV
  16. Common misconceptions
  17. Practical regulatory framework
  18. References and regulatory note

1. What the EU Medicines Regulatory System Is Designed to Do

The EU medicines regulatory system is a networked legal and scientific framework for regulating medicinal products throughout their lifecycle.

Its central objectives include ensuring that medicines meet appropriate standards of quality, safety and efficacy, while providing a functioning framework for authorisation, supervision and access across the European Union.

The system is not simply an approval mechanism. It must continue to operate after authorisation because the evidence surrounding a medicine can change over time.

New information may concern:

The regulatory system therefore has two connected functions:

authorise medicines when the legal and scientific requirements are satisfied, and continue to supervise and regulate them as evidence and circumstances change.

This lifecycle concept is essential for understanding why marketing authorisation, pharmacovigilance, variations, referrals and risk-management procedures belong to the same regulatory system.

2. The EU Does Not Have One Single Medicines Regulator

A common oversimplification is to describe EMA as the EU medicines regulator.

EMA is central to the European regulatory network, but it does not replace the national competent authorities of the Member States.

Different institutions and authorities have different legal functions.

At a high level:

Actor Core role
European Union legislator Establishes the legal framework
European Commission Performs specified executive and regulatory functions, including centralised decisions
EMA Provides scientific assessment, coordination and regulatory-network functions within its legal remit
National competent authorities Regulate medicines nationally and participate in EU procedures
CHMP Scientific assessment of human medicines within its remit
PRAC Pharmacovigilance and safety-risk assessment
CMDh Coordination of nationally authorised medicines under MRP/DCP and related procedures

The exact role of each body depends on the legal procedure.

That qualification matters. A committee can participate in a procedure without being the body that makes the final legally operative decision.

3. The European Regulatory Network

The EU medicines system is best understood as a network rather than a hierarchy in which every decision flows from EMA.

A simplified conceptual model is:

EU medicines legislation
          |
          v
European regulatory framework
          |
    +-----+----------------+
    |                      |
    v                      v
  EMA             National competent authorities
    |                      |
    |              National procedures
    |                      |
    +----------+-----------+
               |
               v
      EU scientific and
      coordination mechanisms
               |
               v
       Regulatory outcome
               |
               v
      National/Union implementation
               |
               v
      Lifecycle supervision

This model is deliberately simplified.

The actual allocation of responsibilities depends on the medicinal product, its authorisation route and the specific legal procedure.

For regulatory professionals, the first question should therefore be which procedure is being used, not simply which agency's website contains the relevant document.

EU medicines regulation is based on EU legislation that establishes substantive requirements and procedural mechanisms.

Two foundational instruments for human medicines are particularly important:

These instruments should not be treated as interchangeable.

The Directive provides a major part of the framework governing nationally authorised medicines and related procedures, while the Regulation establishes the Union-level centralised authorisation system and associated EMA functions.

The legislation has subsequently been amended and supplemented by other EU instruments.

For a live regulatory assessment, the current consolidated legal text and applicable implementing provisions should always be checked.

The same scientific issue can have different procedural consequences depending on the legal status of the product and the circumstances in which the issue arises.

For example, a safety concern involving a centrally authorised medicine can enter a different legal pathway from a comparable concern involving nationally authorised medicines.

Similarly, a disagreement during a mutual-recognition or decentralised procedure can engage a different referral mechanism from a post-authorisation safety concern.

Therefore:

The scientific subject alone does not determine the regulatory procedure.

The relevant legal basis, authorisation status, procedural history and trigger must all be established.

This principle will become particularly important in the later articles on Articles 20, 30, 31 and 107i.

6. Marketing Authorisation Is the Central Regulatory Concept

A medicinal product generally requires a marketing authorisation before it can be placed on the market, subject to the applicable legal framework and exceptions.

A marketing authorisation is not merely a statement that a medicine has been tested and found to work.

It establishes the legally authorised conditions under which the product may be marketed and used.

Depending on the product, the authorised framework can specify matters such as:

The authorisation therefore creates a regulatory baseline against which later changes are assessed.

7. Benefit-Risk Is a Lifecycle Concept

The initial marketing-authorisation assessment asks whether the benefit-risk balance is favourable under the proposed conditions of use.

That conclusion is not necessarily permanent.

After authorisation, additional evidence can alter understanding of:

Consequently, the regulatory system must be capable of changing the authorised conditions when the evidence warrants it.

This is why pharmacovigilance and post-authorisation regulation are not separate from the marketing authorisation system. They are mechanisms for maintaining the regulatory validity of the authorisation over time.

8. The Two Broad Authorisation Families

For a first-pass understanding, EU medicines authorisation can be divided into:

  1. the centralised procedure; and
  2. national procedures.

National procedures include:

The distinction determines where the scientific assessment occurs, how Member States participate and where the resulting authorisation is legally effective.

It does not mean that national procedures operate outside the common EU legal and scientific framework.

9. The Centralised Procedure

The centralised procedure provides a Union route under which a single marketing authorisation can cover the EU market.

The applicant submits a single application through the EMA framework.

For human medicines, CHMP normally performs the principal scientific assessment within the centralised system.

The simplified sequence is:

Applicant
   |
   v
EMA scientific process
   |
   v
CHMP assessment
   |
   v
CHMP scientific opinion
   |
   v
European Commission
   |
   v
Legally binding Union decision

The centralised route is particularly important because it illustrates the distinction between scientific assessment and legal decision-making.

EMA and its scientific committees do not simply equal the legal authorisation authority.

10. Does EMA Approve Centrally Authorised Medicines?

In precise regulatory terminology, it is better not to say that EMA itself grants the centralised marketing authorisation.

EMA coordinates the scientific evaluation and the relevant scientific committee adopts an opinion.

The European Commission subsequently adopts the legally binding decision under the applicable Union procedure.

Therefore, the regulatory sequence is better described as:

EMA scientific assessment → committee opinion → European Commission decision.

The distinction becomes even more important in referrals, where a scientific recommendation or opinion can precede a separate legal decision.

Informal statements such as “EMA approved the product” may be understandable in general communication, but formal regulatory writing should identify the actual legal actor.

11. National Authorisation

A national marketing authorisation is granted by the competent authority of an individual Member State under the applicable national and EU legal framework.

The authorisation is initially limited to that Member State.

National authorisation remains an important component of the EU system because not every medicinal product follows the centralised route.

A nationally authorised medicine can subsequently become subject to EU coordination mechanisms, including MRP, DCP-related procedures, pharmacovigilance procedures and referrals, depending on the circumstances.

Thus:

National authorisation does not mean national regulation in isolation.

The Member State remains the direct regulatory authority for many functions, but it operates within a common European legal and scientific environment.

12. Mutual Recognition Procedure

The mutual recognition procedure is used when a medicinal product already has a national marketing authorisation in one Member State and the applicant seeks recognition of that assessment in additional Member States.

The existing authorisation is associated with the Reference Member State (RMS).

The additional participating states are the Concerned Member States (CMSs).

The central concept is recognition of an existing national assessment within the framework established by EU law.

MRP therefore differs fundamentally from the centralised procedure: the product remains within the national authorisation framework rather than receiving one Union marketing authorisation.

13. Decentralised Procedure

The decentralised procedure is used when the medicinal product has not already been authorised in a Member State and the applicant seeks authorisation in several Member States simultaneously, where the product is eligible for the procedure.

The applicant identifies:

The RMS conducts the principal assessment and prepares the assessment documentation for the participating Member States.

The CMSs participate in the coordinated assessment.

The objective is to achieve a harmonised outcome while retaining national marketing authorisations.

14. MRP and DCP: The Key Difference

The most useful conceptual distinction is the starting point.

Feature MRP DCP
Prior national authorisation Yes No
RMS Yes Yes
CMSs Yes Yes
Basic mechanism Recognition of an existing assessment Coordinated simultaneous assessment
Result National MAs in participating states National MAs in participating states

Both procedures operate within the common EU regulatory framework.

The difference is principally procedural rather than a difference in the scientific standard expected of the medicine.

15. One European Standard, Multiple Regulatory Routes

Different authorisation routes should not be interpreted as different levels of scientific scrutiny.

The EU regulatory framework establishes common requirements for quality, safety and efficacy.

The route determines how the assessment is organised and how the authorisation is granted, not whether a medicine is expected to meet a lower scientific standard.

This is an important corrective to the misconception that a nationally authorised medicine is inherently subject to weaker scientific requirements than a centrally authorised medicine.

The appropriate comparison is procedural architecture, not scientific quality.

16. National Competent Authorities

National competent authorities (NCAs) are the medicines regulators of the EU Member States.

Their responsibilities can include:

NCAs are also deeply integrated into the European regulatory network.

National experts participate in EMA scientific committees and working groups, and national authorities contribute to coordinated EU procedures.

The EU system therefore depends on the interaction of Union-level and national regulatory expertise.

17. The European Medicines Agency

EMA is the central scientific agency of the EU medicines regulatory network.

Its responsibilities extend across the medicine lifecycle and include scientific assessment, pharmacovigilance coordination, scientific guidance, committee support, information and other functions assigned by EU law.

EMA should therefore be understood as both:

  1. a scientific regulatory agency; and
  2. a coordinating hub within a network of national authorities.

It is not a replacement for the national competent authorities.

This network model explains why many EU regulatory procedures involve both EMA-level scientific work and Member State implementation.

18. The European Commission

The European Commission is institutionally distinct from EMA.

Its role includes functions assigned by EU legislation, including important executive and regulatory decisions in the medicines system.

For centralised marketing authorisations, the Commission adopts the legally binding decision following the relevant scientific opinion.

The Commission also participates in the development and implementation of EU pharmaceutical legislation and in specified regulatory procedures.

A precise description of a regulatory event should therefore distinguish:

19. CHMP, PRAC and CMDh

Three bodies are particularly important for understanding the later articles in this series.

CHMP

The Committee for Medicinal Products for Human Use is the principal EMA scientific committee for human medicines within its legal remit.

It assesses centralised applications and performs other scientific functions, including certain referral and post-authorisation assessments.

PRAC

The Pharmacovigilance Risk Assessment Committee is the EU specialist committee for pharmacovigilance and safety-risk assessment.

It evaluates safety signals, risk-management issues, post-authorisation safety studies and pharmacovigilance referrals within its remit.

CMDh

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human coordinates regulatory issues concerning nationally authorised medicines within the MRP/DCP framework and has additional functions assigned by EU law.

These bodies should never be treated as interchangeable.

One of the most important concepts in EU regulatory affairs is the distinction between scientific assessment and legal decision-making.

A scientific committee may evaluate evidence and adopt an opinion or recommendation.

A separate authority may then adopt the legally operative decision required by the applicable legislation.

The simplified model is:

Evidence
   ↓
Scientific assessment
   ↓
Committee opinion / recommendation
   ↓
Legal decision, where required
   ↓
Implementation

This distinction prevents several common errors:

The rest of the EU regulatory system can be understood much more easily once this separation is kept explicit.

The EU medicines regulatory system is built on a combination of Union legislation and national implementation.

For human medicines, two legal instruments are particularly important at a foundational level:

They do different things within the system.

Directive 2001/83/EC establishes the Community code relating to medicinal products for human use and contains extensive provisions governing national authorisation, mutual recognition, decentralised procedures, pharmacovigilance and related regulatory matters.

Regulation (EC) No 726/2004 establishes Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products and establishes EMA.

The detailed legal analysis belongs in a later chapter on EU pharmaceutical legislation. For this introductory article, the important principle is that the regulatory pathway must always be understood against its legal basis.

22. EU Law and National Competent Authorities

EU medicines regulation is neither purely centralised nor purely national.

Union legislation creates common rules and procedures, while national competent authorities retain substantial responsibilities.

This produces a network in which:

Union legislation
       ↓
Common regulatory framework
       ↓
European + national authorities
       ↓
Scientific assessment / coordination
       ↓
Regulatory decision
       ↓
National or Union implementation

The precise route depends on the product and procedure.

A regulatory professional should therefore avoid assuming that a European legal requirement is implemented through a single European authority in every circumstance.

23. The European Regulatory Network

The EU medicines system is commonly described as a regulatory network because responsibilities are distributed among multiple institutions and national authorities.

The network includes:

The network model provides both common standards and distributed expertise.

National authorities contribute scientific expertise, inspections, pharmacovigilance activities and regulatory experience, while EMA coordinates many Union-level scientific processes.

24. Why the Network Model Matters

The network model has practical consequences for regulatory strategy.

A company may interact with:

The relevant participants change according to the procedure.

Consequently, the phrase “the regulator” is often insufficiently precise.

A better question is:

Which authority or committee has responsibility for this particular regulatory act?

One of the most important distinctions in EU regulatory affairs is the difference between scientific assessment and legal decision-making.

Scientific committees assess evidence and formulate scientific conclusions within their legal mandates.

A legal decision-maker then adopts the regulatory instrument required by the applicable legislation.

For a centralised marketing authorisation, the simplified relationship is:

Scientific evidence
       ↓
EMA / CHMP assessment
       ↓
CHMP scientific opinion
       ↓
European Commission
       ↓
Legally binding decision

This distinction also matters in post-authorisation procedures and referrals.

A committee recommendation, opinion or assessment report should not automatically be described as the final legal outcome.

26. The Benefit-Risk Balance

The central regulatory question is not simply whether a medicine has benefits or risks.

Medicines generally have both.

The regulatory question is whether the benefit-risk balance is favourable under the proposed or existing conditions of use.

That assessment can involve:

The balance can change over time as new evidence becomes available.

This is one reason the marketing authorisation should be understood as the beginning of an ongoing regulatory lifecycle rather than the end of regulatory assessment.

27. Quality, Safety and Efficacy

The traditional regulatory pillars are:

Quality — whether the product can be consistently manufactured and controlled to the required standards.

Safety — the nature, frequency, severity and clinical significance of identified and potential risks.

Efficacy — whether the medicine produces the claimed therapeutic effects under the relevant conditions.

These dimensions are interdependent.

For example, a manufacturing change can affect quality and potentially alter clinical performance. A new safety finding can change the benefit-risk balance. New efficacy evidence can alter the assessment of an indication.

Regulatory assessment therefore requires an integrated view rather than treating each dimension as completely isolated.

28. Authorisation Is Conditional

A marketing authorisation should not be interpreted as an unconditional declaration that a medicine is universally safe and effective.

It establishes authorised conditions under which the product may be marketed and used.

Those conditions can include:

The authorised framework can therefore be modified when new evidence justifies regulatory action.

29. Product Information as Part of the Regulatory Framework

The product information communicates important elements of the authorised conditions of use.

For human medicines, this can include:

For centrally authorised medicines, product information is adopted as part of the Union regulatory framework.

For nationally authorised medicines, the applicable national product information operates within the relevant national and EU framework.

Product information should therefore be regarded as a controlled regulatory output rather than simply a marketing document.

30. The Marketing Authorisation Holder

The marketing authorisation holder (MAH) is the legal entity responsible for the marketing authorisation within the applicable regulatory framework.

The MAH has continuing obligations after authorisation.

These can include activities relating to:

The exact obligations depend on the authorisation and applicable legislation.

The important principle is that obtaining an authorisation does not transfer regulatory responsibility to EMA or the national authority.

The MAH remains responsible for meeting its legal and regulatory obligations.

31. Pharmacovigilance Within the EU System

Pharmacovigilance is integrated into the medicines regulatory lifecycle.

After authorisation, evidence can arise from:

This evidence can trigger further scientific assessment and, where justified, regulatory action.

PRAC is a central component of the EU pharmacovigilance framework, but pharmacovigilance is not performed by PRAC alone. National competent authorities, MAHs, healthcare professionals, patients and other stakeholders contribute to the system.

32. Risk Management

EU regulation does not rely solely on detecting adverse events after they occur.

Risk management aims to identify and characterise important risks and establish measures appropriate to the medicine's benefit-risk profile.

The Risk Management Plan (RMP) is a key regulatory instrument for this purpose.

Depending on the product, risk-management activities can include:

Risk management therefore connects scientific evidence with practical regulatory controls.

33. Post-Authorisation Regulation

The regulatory lifecycle continues after the initial authorisation.

Post-authorisation activity can include:

A useful mental model is:

Development
    ↓
Marketing authorisation
    ↓
Marketed medicine
    ↓
Evidence generation
    ↓
Regulatory reassessment
    ↓
Authorisation maintained / modified / restricted
    ↓
Continued surveillance

The lifecycle is iterative rather than linear.

34. Variations

A variation is a regulatory procedure used to change an existing marketing authorisation.

The nature of the variation determines the applicable procedure and requirements.

Changes can involve areas such as:

The variation system allows the authorised product to evolve under controlled regulatory oversight.

The detailed classification of variations will be addressed in a later article.

35. Renewals

Some marketing authorisations require regulatory renewal according to the applicable legal framework.

A renewal is not simply an administrative expiry-date exercise.

The regulatory assessment can consider the continued benefit-risk balance and relevant new information.

The applicable renewal requirements depend on the type of authorisation and current legislation.

36. Referrals

A referral is a formal regulatory procedure used when a defined question must be assessed through the relevant Union mechanism.

Referral procedures can arise from different legal bases and triggers.

Examples relevant to human medicines include:

These procedures are not interchangeable.

Their legal bases, triggers, products in scope, committee roles and outcomes differ.

This distinction will be developed in the dedicated Referral Procedures section of the series.

37. Regulatory Surveillance Is Continuous

The regulatory system continuously receives information about medicines after authorisation.

This can include:

The presence of new information does not automatically mean that regulatory action is required.

The information must be evaluated in context.

The regulatory system therefore combines surveillance with scientific assessment and proportionate decision-making.

38. National and Union-Level Pharmacovigilance

Pharmacovigilance responsibilities are distributed between national authorities, EMA structures and MAHs.

National competent authorities contribute case assessment, signal management, inspections and national regulatory action within their mandates.

EMA coordinates Union-level pharmacovigilance activities and supports scientific committee processes.

MAHs operate their own pharmacovigilance systems and remain responsible for compliance with applicable requirements.

This distributed model means that an important safety issue can move from a national observation into a Union-level assessment when the legal and scientific criteria for doing so are met.

39. The Role of CMDh in the Network

CMDh illustrates how the EU system connects national authorisations with Union-level coordination.

It is particularly relevant to medicines authorised through mutual-recognition and decentralised procedures.

CMDh can facilitate harmonised positions among Member States and has defined roles in procedures involving nationally authorised medicines.

Its function should not be confused with CHMP's role in centralised human-medicine assessment or PRAC's specialist pharmacovigilance role.

The correct committee depends on the legal procedure being applied.

40. The Role of the European Commission After Scientific Assessment

For centralised procedures, the Commission's decision-making role is a key part of the legal architecture.

The Commission does not perform the scientific assessment in the same way as CHMP.

Instead, it acts within the Union decision-making framework on the basis of the relevant scientific and regulatory process.

This illustrates a broader principle:

Scientific expertise and legal authority can be deliberately separated within the regulatory system.

That separation helps distinguish evidence assessment from the formal legal act that establishes the regulatory outcome.

The regulatory consequence of an assessment depends on the procedure.

Possible outputs include:

These outputs should not be treated as legally equivalent.

A regulatory professional should identify the actual instrument and its legal effect before determining implementation requirements.

42. Regulatory Guidance Versus Law

The EU regulatory environment contains both binding legal instruments and non-legislative guidance.

Legislation establishes legal obligations.

Guidance can explain how authorities and applicants are expected to interpret or implement requirements, but its legal status depends on the nature of the document and applicable law.

Therefore:

Guidance should not automatically be treated as legislation.

The legal basis should always be checked when a requirement is described as mandatory.

43. Primary Sources

For a live regulatory question, primary sources should normally be consulted first.

Important sources include:

Secondary articles and regulatory commentary can help explain the system but should not replace the governing document when a specific legal or procedural conclusion is required.

44. Why Dates Matter

EU regulatory requirements can change.

A regulatory professional should therefore distinguish:

The date of a source can materially affect its relevance.

A current question should generally be answered using the current applicable framework unless the purpose is explicitly historical.

45. Regulatory Intelligence

Regulatory intelligence is the structured process of identifying and interpreting information that may affect regulatory strategy or compliance.

Within the EU medicines system, relevant intelligence can include:

The value of regulatory intelligence lies not merely in collecting information but in determining whether the information changes the company's regulatory obligations or strategy.

46. The MAH's Internal Regulatory System

A mature MAH should mirror the external regulatory lifecycle internally.

A simplified model is:

External regulatory requirement
            ↓
Internal assessment
            ↓
Impact determination
            ↓
Cross-functional action
            ↓
Controlled implementation
            ↓
Verification
            ↓
Regulatory closure

This is particularly important when a regulatory outcome affects several functions simultaneously.

47. The QPPV Within the Broader System

The Qualified Person Responsible for Pharmacovigilance (QPPV) operates within the pharmacovigilance component of this broader regulatory framework.

The QPPV's responsibilities do not mean that the QPPV is the decision-maker for every regulatory issue.

Instead, the QPPV needs sufficient oversight of the pharmacovigilance system and relevant safety information to ensure that the MAH can meet applicable pharmacovigilance obligations.

This creates an important interface between:

48. Why Regulatory Affairs and Pharmacovigilance Must Interact

A safety finding may begin in pharmacovigilance but eventually require regulatory action.

Conversely, a regulatory decision can create new pharmacovigilance obligations.

Examples include:

The interface should therefore be managed through defined processes rather than informal communication.

49. A Practical Regulatory Mental Model

For most EU medicines questions, start with five questions:

  1. What product is involved?
  2. Where is it authorised?
  3. What legal procedure is being used?
  4. Which authority or committee has responsibility?
  5. What is the legally operative outcome?

These questions prevent many common regulatory misunderstandings.

They also provide the foundation for understanding the more specialised articles that follow in this series.

50. The System as a Lifecycle

The EU medicines regulatory system can ultimately be understood as a continuous lifecycle:

Research and development
          ↓
Regulatory strategy
          ↓
Marketing authorisation
          ↓
Manufacturing and supply
          ↓
Marketed use
          ↓
Pharmacovigilance and surveillance
          ↓
Scientific reassessment
          ↓
Variations / renewals / referrals / other action
          ↓
Updated authorised conditions
          ↓
Continued monitoring

No single institution owns every stage.

The system works because different authorities and organisations perform defined functions within a shared legal framework.

That is the central idea needed to understand EU medicines regulation as a whole.

51. How a Regulatory Question Should Be Classified

Before selecting a regulatory procedure, first classify the question.

A question may concern:

The classification does not by itself determine the legal procedure, but it provides the starting point for identifying the relevant regulatory framework.

A common error is to select a familiar procedure before establishing what legal question actually needs to be resolved.

52. Product Status Comes Before Procedure Selection

The regulatory status of the medicine is another critical variable.

Ask whether the product is:

The same scientific issue can have different regulatory pathways depending on that status.

For example, a safety question involving a centrally authorised medicine may follow a different statutory route from a question concerning nationally authorised medicines.

53. The Four Major Authorisation Routes

At a high level, human medicines in the EU can reach the market through four broad routes:

  1. centralised procedure;
  2. national procedure;
  3. mutual recognition procedure;
  4. decentralised procedure.

These routes should be understood as distinct regulatory architectures rather than merely different application forms.

They determine who assesses the application, where the resulting authorisation operates and how disagreement is managed.

54. Centralised Procedure: One Union Authorisation

The centralised procedure results in a single marketing authorisation that is valid throughout the EU and the European Economic Area countries covered by the applicable framework.

The scientific assessment is conducted through the EMA system, principally by CHMP for human medicines.

The European Commission adopts the corresponding Union marketing-authorisation decision.

The centralised route is mandatory for certain categories of medicines specified by EU legislation and available or optional for others according to the applicable legal framework.

The exact eligibility rules should always be checked against current legislation.

55. National Procedure

A national procedure is conducted by a Member State's national competent authority under the applicable EU and national framework.

The resulting authorisation applies within that Member State.

A company seeking authorisation in several Member States may therefore need to use another regulatory route or coordinate national authorisations through the applicable procedures.

National competent authorities remain important throughout the lifecycle, including for inspections, pharmacovigilance and national regulatory implementation.

56. Mutual Recognition Procedure

The Mutual Recognition Procedure (MRP) is used where a medicine has already received a national marketing authorisation in one Member State and the applicant seeks recognition of that authorisation in other Member States.

The Member State whose existing assessment is relied upon is the Reference Member State (RMS).

The other participating Member States are Concerned Member States (CMSs).

The system is designed to allow reliance on an existing assessment while maintaining the involvement of the participating national authorities.

57. Decentralised Procedure

The Decentralised Procedure (DCP) is used when the medicine has not yet received a national marketing authorisation in the participating Member States and the applicant seeks authorisation in several Member States simultaneously.

One Member State acts as RMS and prepares the assessment, while CMSs participate in the procedure.

The resulting national authorisations are issued by the participating Member States.

The DCP and MRP therefore combine common scientific assessment with national authorisation structures.

58. RMS and CMS: Why the Roles Matter

The RMS coordinates the assessment in MRP and DCP procedures.

CMSs participate in the assessment and consider whether the RMS assessment can be recognised or accepted under the applicable procedure.

If disagreement cannot be resolved through the normal procedure, the legal framework provides escalation mechanisms.

This is why the distinction between RMS and CMS is not merely administrative terminology.

It describes the allocation of regulatory responsibilities within the procedure.

59. What Happens When Member States Disagree?

The EU framework contains mechanisms for resolving significant disagreements.

The appropriate route depends on the legal context and the nature of the disagreement.

A disagreement may concern:

The existence of disagreement does not itself identify the final procedure.

The applicable legal provision must be established first.

60. Article 29(4) as an Example of Escalation

Article 29(4) of Directive 2001/83/EC provides an important example of how disagreement can move beyond the MRP or DCP framework.

Where Member States cannot reach agreement during the relevant procedure because of a potential serious risk to public health, the matter can be referred for Union-level assessment under the applicable referral mechanism.

The case can then move into a CHMP assessment and ultimately into the applicable Union decision-making framework.

This should not be confused with other referral procedures merely because CHMP becomes involved.

The legal trigger and procedural history determine the route.

Regulatory procedures should be identified by their legal basis and trigger rather than by their most visible committee.

For example, saying that “CHMP assessed the issue” does not by itself establish whether the matter was an Article 30 referral, an Article 31 referral, an Article 29(4) referral or another procedure.

A proper regulatory description should therefore identify:

  1. legal basis;
  2. trigger;
  3. product status;
  4. initiating authority;
  5. committee role;
  6. final regulatory instrument.

62. Article 20 Procedures

Article 20 of Regulation (EC) No 726/2004 provides a specific pharmacovigilance-related mechanism for centrally authorised medicines.

It should therefore not be treated as a generic “EMA safety referral.”

Its legal basis, trigger and procedural mechanics are distinct.

This is one reason the referral articles in this series are separated by legal procedure rather than grouped into one generic safety-referral chapter.

63. Article 31 Procedures

Article 31 of Directive 2001/83/EC provides a Union-interest referral mechanism.

It contains distinct pathways depending on whether the procedure is initiated following evaluation of pharmacovigilance data or data other than pharmacovigilance data.

The relevant committee pathway and regulatory mechanics consequently depend on the nature of the referral.

A professional should therefore avoid using “Article 31” as if it described one uniform scientific process.

64. Article 107i Urgent Union Procedures

Article 107i provides an urgent Union procedure associated with pharmacovigilance concerns.

Its purpose is to enable rapid Union-level assessment where the statutory conditions for the urgent procedure are met.

Urgency affects the regulatory timetable and operational response, but urgency should not be confused with the legal basis itself.

The precise procedural requirements should be checked against current legislation and EMA guidance.

65. Why Referral Types Need a Separate Comparative Framework

The major referral procedures can appear superficially similar because they can involve EMA committees, scientific assessment and regulatory action.

Their differences become clear when compared systematically.

Feature Key question
Legal basis Which EU provision applies?
Trigger Why was the procedure initiated?
Product status Centralised or nationally authorised?
Initiator Which authority or body initiated it?
Committee PRAC, CHMP, CMDh or another body?
Evidence Safety, quality, efficacy or other data?
Outcome Opinion, position, decision or national action?

This comparative method will be used in the dedicated referral chapter.

66. Scientific Committees Are Procedure-Specific

The EU has several scientific committees and coordination bodies because different regulatory questions require different expertise and legal mandates.

For human medicines, important bodies include:

Their roles overlap at the level of the broader regulatory network but are not interchangeable.

A committee's involvement should therefore be interpreted in the context of the procedure under which it is acting.

67. CHMP

The Committee for Medicinal Products for Human Use (CHMP) is the EMA committee responsible for preparing scientific opinions on questions concerning human medicines within its mandate.

Its responsibilities include centralised marketing-authorisation assessments and specified referral and post-authorisation procedures.

CHMP is therefore a major scientific decision point in the EU system, but it is important to distinguish its scientific opinion from the legal decision that may follow.

68. PRAC

The Pharmacovigilance Risk Assessment Committee (PRAC) is the EMA committee responsible for assessing and monitoring safety issues relating to human medicines.

Its work includes pharmacovigilance questions, risk-management considerations and safety-related regulatory procedures within its legal mandate.

PRAC's specialist role makes it central to EU pharmacovigilance, but PRAC does not replace the other scientific and regulatory bodies in the system.

69. CMDh

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) operates within the framework for nationally authorised human medicines.

It is particularly important for MRP and DCP coordination and for resolving or managing specified regulatory disagreements involving Member States.

CMDh should therefore be understood as a key component of the national-authorisation network rather than as an equivalent of CHMP.

70. National Competent Authorities

National competent authorities remain fundamental to EU medicines regulation.

Their responsibilities can include:

Even where a procedure is coordinated at Union level, national authorities can retain important implementation and oversight functions.

71. European Commission

The European Commission has important legal and policy functions within the EU medicines framework.

For centrally authorised medicines, it adopts the Union marketing-authorisation decision following the applicable scientific process.

It also has broader responsibilities concerning implementation of EU pharmaceutical legislation and the adoption of certain legally binding measures.

Its role should therefore be distinguished from EMA's scientific and coordination functions.

72. EMA

EMA coordinates scientific expertise and regulatory processes at Union level.

Its functions include supporting scientific committees, coordinating assessments, maintaining regulatory information and facilitating the operation of the European medicines regulatory network.

EMA is therefore not simply a European equivalent of a national medicines authority.

It operates within a distributed network and has responsibilities defined by Union law.

73. The Relationship Between EMA and National Authorities

EMA and national competent authorities are complementary rather than competing institutions.

National authorities provide expertise, regulatory capacity and implementation within Member States.

EMA provides Union-level coordination and scientific infrastructure for procedures within its mandate.

The network allows expertise from different Member States to contribute to Union regulatory assessment.

74. The European Commission, EMA and Committees

A simplified model is:

European Union legislation
          ↓
European Commission / legal framework
          ↓
EMA regulatory network
          ↓
Scientific committees
   ┌──────┼──────┐
 CHMP    PRAC   CMDh
   │       │      │
   └──────┴──────┘
          ↓
National competent authorities
          ↓
Implementation and supervision

This is a conceptual diagram rather than a literal organisational chart.

The exact relationships depend on the legal procedure.

75. The Importance of Procedure-Specific Timelines

EU regulatory procedures operate according to defined procedural steps and, where applicable, formal timetables.

However, there is no single universal “EMA timeline.”

Timelines depend on:

Therefore, generic timing statements should never replace the timetable for the actual procedure.

76. Clock-Stops and Responses

Many scientific regulatory procedures allow periods during which the applicant or MAH prepares responses to questions.

These periods can affect the procedural calendar.

A regulatory team should distinguish:

This distinction is particularly important when planning regulatory submissions or product-information changes.

77. Regulatory Questions Are Evidence Questions

A regulator's question should normally be translated into an evidence problem.

For example:

Regulatory question
       ↓
What evidence would answer it?
       ↓
Where is that evidence?
       ↓
What are its limitations?
       ↓
What conclusion does it support?

This approach helps prevent responses that merely restate existing information without addressing the actual regulatory concern.

78. Evidence Quality Matters

Regulatory assessment considers more than the number of studies or reports available.

Relevant factors can include:

The appropriate evidentiary standard depends on the regulatory question and legal context.

79. Regulatory Uncertainty

Scientific uncertainty is an inherent feature of medicines regulation.

A medicine may have incomplete information about:

Regulatory decision-making therefore often involves weighing evidence under uncertainty rather than waiting for complete certainty.

Risk-management measures can be used where appropriate to manage residual uncertainty.

80. Proportionality

Regulatory action should be considered in relation to the evidence, the risk and the available regulatory options.

Possible actions can range from no change through information updates and additional monitoring to restrictions or withdrawal, depending on the legal framework and evidence.

The existence of a risk does not automatically determine one particular regulatory response.

The response must be justified within the applicable regulatory framework.

81. Communication Is Part of Implementation

A regulatory outcome is not fully implemented merely because the legal decision has been issued.

Depending on the outcome, implementation can require:

The exact requirements depend on the final regulatory instrument.

82. Documentation and Traceability

A robust regulatory system should allow each major conclusion to be traced back to its source.

A useful structure is:

Legal requirement
       ↓
Regulatory question
       ↓
Evidence
       ↓
Assessment
       ↓
Decision
       ↓
Implementation
       ↓
Verification

Traceability is important for regulatory submissions, inspections, audits and future regulatory decisions.

83. The Regulatory File

The regulatory file should preserve the history necessary to reconstruct the procedure.

Depending on the procedure, this may include:

The exact document set depends on the legal pathway.

The objective is not simply document storage but reliable reconstruction of regulatory reasoning and action.

84. Internal Change Control

When a regulatory outcome changes an authorised condition, implementation should normally be controlled through the company's established change-management processes.

The change should identify:

This creates an auditable bridge between the external regulatory decision and internal implementation.

85. A Regulatory Professional's First Five Checks

When confronted with a new EU medicines regulatory issue, begin with:

  1. Identify the product and authorisation status.
  2. Identify the legal basis.
  3. Identify the regulatory trigger.
  4. Identify the responsible authority or committee.
  5. Identify the operative regulatory consequence.

Only after these five checks should detailed procedural interpretation begin.

86. Closing Framework for the EU Regulatory System

The EU medicines regulatory system is best understood as a distributed lifecycle system operating under common Union law.

Its defining characteristics are:

The system is complex because medicines regulation is complex.

But the complexity becomes manageable when every question is anchored to the same framework:

What medicine?
      ↓
Where authorised?
      ↓
Which legal basis?
      ↓
Which procedure?
      ↓
Which authority / committee?
      ↓
What evidence?
      ↓
What scientific conclusion?
      ↓
What legal outcome?
      ↓
What implementation?
      ↓
What ongoing obligation?

That framework provides the foundation for the next article in this series: What Is a Marketing Authorisation in the EU?

References

  1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. This is a principal legal foundation for the EU framework governing human medicines, including national authorisation, mutual recognition, decentralised procedures and pharmacovigilance.
  2. European Parliament and Council. Regulation (EC) No 726/2004, as amended. This establishes Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products and establishes the European Medicines Agency.
  3. European Medicines Agency. The European regulatory system for medicines. Current EMA explanatory material describing the European medicines regulatory network, EMA and national competent authorities.
  4. European Medicines Agency. Marketing authorisation. Current EMA information concerning centralised marketing-authorisation procedures and the role of scientific assessment.
  5. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Current information concerning CHMP's scientific responsibilities for human medicines.
  6. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Current information concerning PRAC's responsibilities for pharmacovigilance and safety assessment.
  7. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Current information concerning CMDh and nationally authorised medicines.
  8. European Commission. Pharmaceutical legislation. Current European Commission material concerning the EU legislative framework for medicinal products.
  9. European Medicines Agency. Referral procedures for human medicines. Current EMA information concerning the principal Union referral mechanisms and their legal context.
  10. European Commission / European Medicines Agency. Notice to Applicants and current procedural guidance. Current procedural material should be consulted for application-specific requirements and timelines.
  11. European Medicines Agency. Good Pharmacovigilance Practices (GVP). Current guidance relevant to pharmacovigilance systems, risk management, signal management and post-authorisation safety activities.
  12. European Medicines Agency. Risk-management plans. Current information concerning RMPs and their role in the benefit-risk lifecycle.

Primary-document hierarchy

For a live regulatory question, primary sources should take precedence over secondary explanations. A practical hierarchy is:

  1. applicable EU legislation and its current consolidated version;
  2. the formal procedure-specific regulatory document;
  3. the final legally operative decision or applicable CMDh position;
  4. adopted committee opinion or recommendation, where applicable;
  5. procedure-specific assessment reports and annexes;
  6. current EMA, CMDh and European Commission guidance;
  7. public summaries and secondary commentary.

The appropriate primary source depends on the question. For example, a question about the legal effect of a regulatory action should be answered from the applicable legal instrument, whereas a question about the scientific reasoning may require the relevant assessment report and committee conclusion.

Regulatory Note

This article is an educational and regulatory-reference document. It explains the structure of the European Union medicines regulatory system and is intended to provide a conceptual foundation for more specialised articles in this series.

It is not legal advice and should not be used as a substitute for the applicable EU legislation, current consolidated legal texts, EMA guidance, CMDh guidance, national competent-authority requirements or procedure-specific regulatory documents.

EU medicines legislation and regulatory guidance are amended periodically. The current applicable framework should therefore be checked whenever a live regulatory decision is being assessed.

The article deliberately distinguishes general regulatory principles from procedure-specific requirements. The exact legal basis, authority, committee role, timetable, scientific standard and implementation requirement must be established from the documents governing the individual procedure.

In particular, do not infer a binding regulatory obligation solely from a general EMA webpage, scientific discussion, committee meeting summary or secondary source. Where a specific regulatory action is being assessed, the applicable legislation and final procedure-specific regulatory instrument should be reviewed.

The article's later chapters address individual procedures in greater depth. Those chapters should be read as specialised explanations of the broader framework established here rather than as substitutes for the governing legal documents.

Where an individual regulatory procedure is underway, the current applicable legislation, formal regulatory communications, procedure-specific timetable and legally operative decision take precedence over generic descriptions in this article.

Revision History

Related Articles

EMA Referral Types Explained: Article 20, Article 31, Article 107i and Article 30

A textbook guide to distinguishing Article 20, Article 31, Article 107i and Article 30 referrals in EU medicines regulation, with particular attention to pharmacovigilance, Union interest, urgency, harmonisation and the roles of PRAC, CHMP and CMDh.

EMA, European Commission, National Competent Authorities, CHMP, PRAC and CMDh: Who Does What?

How EMA, the European Commission, national competent authorities, CHMP, PRAC and CMDh interact, what each body is responsible for, and why their roles should not be conflated.

What Happens After a PRAC Recommendation? CHMP, CMDh and the European Commission

How a PRAC recommendation moves through the EU regulatory system, including the roles of CHMP, CMDh and the European Commission and the distinction between scientific recommendations, opinions, positions and legally binding decisions.

Last reviewed: 2026-08-23